Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Beishengyan Pharmaceutical Technology is a subsidiary of the Beijing Institute of Biological Products (BIBP), which operates under the China National Biotec Group (CNBG), a part of Sinopharm. The company is primarily focused on the research, development, and production of vaccines and biological products. It gained significant global prominence for its role in the development and manufacturing of the Sinopharm BIBP COVID-19 vaccine (BBIBP-CorV). Beyond COVID-19, the entity is involved in the broader portfolio of infectious disease prevention, leveraging its extensive manufacturing infrastructure in Beijing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Beishengyan Pharmaceutical Technology.